EP4272750A3 - Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique - Google Patents

Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique Download PDF

Info

Publication number
EP4272750A3
EP4272750A3 EP23182914.4A EP23182914A EP4272750A3 EP 4272750 A3 EP4272750 A3 EP 4272750A3 EP 23182914 A EP23182914 A EP 23182914A EP 4272750 A3 EP4272750 A3 EP 4272750A3
Authority
EP
European Patent Office
Prior art keywords
disease
fusion proteins
protection against
provide protection
protein antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23182914.4A
Other languages
German (de)
English (en)
Other versions
EP4272750A2 (fr
Inventor
Richard Malley
Yingjie Lu
Fan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Medical Center Corp
Original Assignee
Childrens Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center Corp filed Critical Childrens Medical Center Corp
Publication of EP4272750A2 publication Critical patent/EP4272750A2/fr
Publication of EP4272750A3 publication Critical patent/EP4272750A3/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP23182914.4A 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique Pending EP4272750A3 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762062P 2013-02-07 2013-02-07
EP14748672.4A EP2953638B1 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
PCT/US2014/015254 WO2014124228A1 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP14748672.4A Division EP2953638B1 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique

Publications (2)

Publication Number Publication Date
EP4272750A2 EP4272750A2 (fr) 2023-11-08
EP4272750A3 true EP4272750A3 (fr) 2024-01-24

Family

ID=51300148

Family Applications (2)

Application Number Title Priority Date Filing Date
EP14748672.4A Active EP2953638B1 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
EP23182914.4A Pending EP4272750A3 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP14748672.4A Active EP2953638B1 (fr) 2013-02-07 2014-02-07 Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique

Country Status (7)

Country Link
US (2) US11576958B2 (fr)
EP (2) EP2953638B1 (fr)
JP (2) JP6494527B2 (fr)
AU (2) AU2014214844B2 (fr)
CA (1) CA2900008A1 (fr)
ES (1) ES2959258T3 (fr)
WO (1) WO2014124228A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
EP3436061A4 (fr) * 2016-03-31 2019-12-04 Liffey Biotech Limited Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
WO2018156468A1 (fr) * 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Formulations de vaccin pneumococcique conjugué
CN110730670A (zh) 2017-03-28 2020-01-24 儿童医疗中心有限公司 基于多抗原提呈系统(maps)的金黄色葡萄球菌疫苗、免疫原性组合物以及它们的用途
US10525119B2 (en) 2017-03-31 2020-01-07 Boston Medical Center Corporation Methods and compositions using highly conserved pneumococcal surface proteins
KR20200018787A (ko) * 2017-05-22 2020-02-20 더 칠드런스 메디칼 센터 코포레이션 마이코박테리움 투버큘로시스에 대한 혼합 백신
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
GB201807380D0 (en) 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
JP7437385B2 (ja) * 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
BR112021004193A2 (pt) * 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
TW202035436A (zh) * 2018-09-12 2020-10-01 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
KR20220149572A (ko) * 2020-03-03 2022-11-08 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 지카 바이러스 폴리펩티드
WO2022031087A1 (fr) * 2020-08-07 2022-02-10 (주)셀트리온 Composition immunogène comprenant des conjugués polysaccharide pneumococcique-substance dérivée de paroi de cellulaire
EP4398933A1 (fr) 2021-09-09 2024-07-17 Affinivax, Inc. Vaccins antipneumococciques multivalents

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077021A2 (fr) * 2001-03-27 2002-10-03 Chiron Srl. Proteines et acides nucleiques de streptococcus pneumoniae
WO2012155007A1 (fr) * 2011-05-11 2012-11-15 Children's Medical Center Corporation Composition immunogène présentant de multiples antigènes, procédés et utilisations associés

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0296158B1 (fr) 1986-03-06 1992-06-17 Commonwealth Scientific And Industrial Research Organisation ESSAI $i(IN VITRO) PERMETTANT DE DETECTER DES REPONSES IMMUNITAIRES CELLULAIRES
CA1283827C (fr) 1986-12-18 1991-05-07 Giorgio Cirelli Dispositif pour l'injection de formules liquides
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH0372423A (ja) 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (fr) 1991-01-28 2004-11-16 Peter J. Kniskern Vaccin conjugue de polysaccharide contre les pneumocoques
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5674698A (en) 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
WO1995024176A1 (fr) 1994-03-07 1995-09-14 Bioject, Inc. Dispositif de remplissage d'ampoule
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
ATE241384T1 (de) 1995-03-22 2003-06-15 Jackson H M Found Military Med Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69737125T3 (de) * 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae-Antigene und Impfstoffe
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
ATE278418T1 (de) 1997-04-24 2004-10-15 Jackson H M Found Military Med Kopplung unmodifizierter proteinen an haloacyl- oder dihaloacyl-derivatisierten polysacchariden zur herstellung von protein-polysaccharide impfstoffen
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
HUP0002475A3 (en) 1997-07-21 2002-01-28 Baxter Healthcare S A Wallisel Modified immunogenic pneumolysin compositions as vaccines
AU9310298A (en) 1997-09-09 1999-03-29 Trustees Of Columbia University In The City Of New York, The T-independent conjugate-vaccines
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP2053126A1 (fr) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Protéines de pneumonie à streptocoques et molécules d'acide nucléique
EP1144640A3 (fr) * 1998-07-27 2001-11-28 Microbial Technics Limited Acides nucleiques et proteines de streptococcus pneumoniae
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PT1140157E (pt) 1998-12-21 2009-05-06 Medimmune Inc Proteínas de streptococcus pneumoniae e fragmentos imunogénicos para vacinas
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
US20030091593A1 (en) 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003024481A2 (fr) 2001-09-14 2003-03-27 Cytos Biotechnology Ag Emballage de substances immunnostimulatrices dans des particules de type virus : procede de preparation et utilisation correspondants
AU2002364783A1 (en) 2001-11-21 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
RU2378008C2 (ru) 2002-05-14 2010-01-10 Новартис Вэксинес Энд Дайэгностикс С.Р.Л. Комбинированные вакцины против бактериального менингита для введения через слизистую оболочку
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20060121058A1 (en) 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
AU2003291365B2 (en) 2002-11-07 2009-06-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
US20060251675A1 (en) 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2522238A1 (fr) 2003-04-15 2004-10-28 Intercell Ag Antigenes s-pneumoniae
CN1819843A (zh) 2003-05-07 2006-08-16 安万特巴斯德公司 增强脑膜炎球菌疫苗接种免疫原性的方法
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
US20070014807A1 (en) 2003-09-03 2007-01-18 Maida Anthony E Iii Multiplex vaccine
US7786288B2 (en) 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
US20070128183A1 (en) 2004-04-27 2007-06-07 Intercell Ag Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
ATE512230T1 (de) 2004-08-18 2011-06-15 Univ Alberta Proteinherstellungsverfahren unter nutzung von yebf
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CN101107009B (zh) 2005-01-20 2014-08-06 伊斯克诺瓦公司 包含纤连蛋白结合蛋白或纤连蛋白结合肽的疫苗组合物
WO2006084466A2 (fr) 2005-02-11 2006-08-17 Ace Biosciences A/S Polypeptides de streptococcus pneumoniae situes en surface
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
AU2006321888A1 (en) 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
WO2007081583A2 (fr) 2006-01-04 2007-07-19 Children's Medical Center Corporation Préparations anti-pneumococciques et méthodes d'utilisation
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20100226932A1 (en) 2006-02-22 2010-09-09 Novavax, Inc. Adjuvant and Vaccine Compositions
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
WO2007149982A2 (fr) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnostic en matière de maladies auto-immunes
CA2690973A1 (fr) 2006-06-23 2007-12-27 Paul M. Simon Conjugues immunitaires cibles
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
WO2008033966A2 (fr) 2006-09-12 2008-03-20 Alphavax, Inc. Particules de réplicon d'alphavirus correspondant à des antigènes de protéines utilisées en qualité d'adjuvants immunologiques
EP2066346B1 (fr) 2006-09-12 2019-07-03 AlphaVax, Inc. Particules de réplicon d'alphavirus utilisées en tant qu'adjuvants immunologiques
DK2099485T3 (en) 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
EP2104512A2 (fr) 2006-12-21 2009-09-30 Emergent Product Development UK Limited Proteines de streptococcus et leur utilisation comme vaccins
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
WO2008119358A2 (fr) 2007-03-30 2008-10-09 Ace Biosciences A/S Polypeptides de streptococcus pneumoniae situés en surface pour une utilisation dans des compositions de vaccin
AU2008287286B2 (en) 2007-04-13 2013-10-10 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CN101883583B (zh) 2007-06-26 2017-05-17 葛兰素史密丝克莱恩生物有限公司 含有肺炎链球菌荚膜多糖缀合物的疫苗
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2176291A1 (fr) 2007-08-10 2010-04-21 Wacker Chemie AG Expression d'igg pleine longueur et sécrétion dans le milieu de culture de cellules procaryotes
US8840906B2 (en) 2007-08-31 2014-09-23 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung disease and conditions
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
EP2293815A4 (fr) * 2008-05-22 2013-04-03 Childrens Medical Center Conjugué immunogène synergique protéine de fusion-polysaccharide
JP2012512257A (ja) 2008-12-17 2012-05-31 ジェノセア バイオサイエンシーズ， インコーポレイテッド クラミジア抗原およびその使用
US8758766B2 (en) 2008-12-24 2014-06-24 The Kingdom of The Netherlands, Represented by The Mininster of Health, Welfare and Sport, on Behalf of The Minster The National Institute of Public Health and The Environment Modified Streptococcus pneumoniae pneumolysin (PLY) polypeptides
EP2208787A1 (fr) 2009-01-19 2010-07-21 Université de Liège Polypeptide d'alpha-hémolysine recombinant de Staphylococcus aureus doté d'une suppression dans le domaine de la branche et des insertions de séquences hétérologues
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
JP5771605B2 (ja) 2009-05-22 2015-09-02 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物および方法
WO2011008548A1 (fr) 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccins et compositions contre le streptococcus pneumoniae
WO2011044576A2 (fr) 2009-10-09 2011-04-14 Children's Medical Center Corporation Vaccin à cellules entières à dissociation sélective
EP2335721A1 (fr) 2009-12-21 2011-06-22 Institut Pasteur Système d'administration pour antigène contenant streptavidin et biotin
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
WO2011137354A2 (fr) 2010-04-30 2011-11-03 Augmenta Biologicals, Llc Protéines à délivrer
AU2011316924A1 (en) 2010-10-20 2013-05-02 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
WO2012100234A1 (fr) 2011-01-20 2012-07-26 Genocea Biosciences, Inc. Vaccins et compositions contre streptococcus pneumoniae
EP2804627B1 (fr) 2012-01-20 2019-08-14 Genocea Biosciences Inc. Vaccins et compositions antigéniques fusionnés contre streptococcus pneumoniae
WO2014018904A1 (fr) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Vaccins à antigène fusionné et compositions dirigées contre streptococcus pneumoniae
KR102225282B1 (ko) 2015-07-21 2021-03-10 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
TW202035436A (zh) 2018-09-12 2020-10-01 美商兒童醫療中心公司 肺炎鏈球菌融合蛋白疫苗
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002077021A2 (fr) * 2001-03-27 2002-10-03 Chiron Srl. Proteines et acides nucleiques de streptococcus pneumoniae
WO2012155007A1 (fr) * 2011-05-11 2012-11-15 Children's Medical Center Corporation Composition immunogène présentant de multiples antigènes, procédés et utilisations associés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FAN ZHANG ET AL: "Multiple antigen-presenting system (MAPS) to induce comprehensive B- and T-cell immunity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 13 August 2013 (2013-08-13), United States, pages 13564 - 13569, XP055282370, Retrieved from the Internet <URL:http://www.pnas.org/content/110/33/13564.full.pdf?with-ds=yes> [retrieved on 20160621], DOI: 10.1073/pnas.1307228110 *

Also Published As

Publication number Publication date
ES2959258T3 (es) 2024-02-22
CA2900008A1 (fr) 2014-08-14
WO2014124228A1 (fr) 2014-08-14
EP4272750A2 (fr) 2023-11-08
US20150374811A1 (en) 2015-12-31
EP2953638A4 (fr) 2016-08-03
EP2953638B1 (fr) 2023-07-05
JP2019108375A (ja) 2019-07-04
US11576958B2 (en) 2023-02-14
JP6494527B2 (ja) 2019-04-03
EP2953638A1 (fr) 2015-12-16
AU2014214844B2 (en) 2017-12-14
AU2018201768A1 (en) 2018-04-05
AU2014214844A1 (en) 2015-08-13
JP6916828B2 (ja) 2021-08-11
US20230081705A1 (en) 2023-03-16
JP2016509011A (ja) 2016-03-24
AU2018201768B2 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
EP4272750A3 (fr) Antigènes de protéine qui confèrent une protection contre une colonisation et/ou une maladie pneumococcique
MX2021010519A (es) Proteinas f de rsv de prefusion y su uso.
SA518390954B1 (ar) لقاحات علاجية لفيروس الورم الحليمي البشري 18
IN2014CN04187A (fr)
WO2014113490A3 (fr) Peptides wt-1 immunogènes et leurs procédés d&#39;utilisation
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
MX2018007198A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
SG10201903349YA (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
BR112016019525A2 (pt) construções de proteína uspa2 e seu uso
WO2017066706A8 (fr) Souches recombinées vaccinales de listeria et leurs méthodes d&#39;utilisation en immunothérapie anticancéreuse
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
WO2017214596A8 (fr) Compositions et procédés pour prévenir et traiter l&#39;infection par le virus zika
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
MX2015016627A (es) Vacuna para la malaria.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
WO2017142843A8 (fr) Nouvel antigène destiné à être utilisé dans un vaccin antipaludique
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
NZ725212A (en) Group a streptococcus vaccine
PH12015502844B1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof
WO2019099578A8 (fr) Utilisation d&#39;imidazopyrimidine pour moduler une réponse immunitaire humaine
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.
GB2515222A (en) Use of flagellin as a vaccine
WO2015149016A3 (fr) Vaccins contre le cancer du sein et des ovaires
EA033248B1 (ru) Композиция и способ индукции иммунного ответа

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 2953638

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: A61K0039090000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/00 20060101ALI20231218BHEP

Ipc: A61K 39/09 20060101AFI20231218BHEP

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE CHILDREN'S MEDICAL CENTER CORPORATION